Last reviewed · How we verify
CDDP, 5 Fu — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
CDDP, 5 Fu (CDDP, 5 Fu) — Gustave Roussy, Cancer Campus, Grand Paris. Combines cisplatin's DNA crosslinking with 5-FU's inhibition of thymidylate synthase to disrupt DNA synthesis and repair in cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CDDP, 5 Fu TARGET | CDDP, 5 Fu | Gustave Roussy, Cancer Campus, Grand Paris | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CDDP, 5 Fu CI watch — RSS
- CDDP, 5 Fu CI watch — Atom
- CDDP, 5 Fu CI watch — JSON
- CDDP, 5 Fu alone — RSS
Cite this brief
Drug Landscape (2026). CDDP, 5 Fu — Competitive Intelligence Brief. https://druglandscape.com/ci/cddp-5-fu. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing